# <u>Comprehensive Treatment Plan</u> (Original case submitted by Dr. Nicholas DuVall)

#### **BIOGRAPHICAL INFORMATION:**

#### Patient Introduction/Data:

The patient is a 50 year-old African-American female who recently moved to San Antonio, TX from South Carolina. The patient is currently employed in the health care field. The patient states she recently had a dental evaluation but declined treatment due to finances. The patient reports a past dental history of primarily episodic/symptomatic dental treatment consisting of extractions to alleviate the pain.

#### **Medical History:**

	DEN	COMPLETE IN INF	AL HISTORY			
NAME (Last, First, Midd	(Den Promin Solger) Se Instantj	La de Produ Arter 1974 - Las L'SPONSOR	S SSN BIRTHD	ATE ACTIV SDirds Ga Far	E DUTY C	SNLV Nez - Are Ini
ORGANIZATION Mon	e Duty/ or Home Address	-DLITY PSK	ANE I HOME PHONE	0	Type	1 20
EMAIL ADDRESS (MIL	Tary Address)			STATUS?	VES	NO
The Answere To R	a Ecklowing Ourstions Will Assist	The Dentist In Evaluating	Your General Health Prior To	SCL or PSIP	and Treater	test
PLEA	SE READ CAREFULLY AND	ANSWER EACH QUI	STION AS ACCURATE	LY AS POSSIBLE	E	
GOOD I PLEASE DRAW A C	IRCLE AROUND ANY OF THE F	FOLLOWING WHICH Y	2009 NU HAVE HAD OR HAVE A	T PRESENT	-1	
Hast Disease or Canobias Argens Peters Page House Paster Page House Paster Stormes of Breath Swolken Articles Artificias Hann Valva Chargentia Hann Valva Chargentia Hann Valva Chargentia Hann Valva Chargentia Hanna Haut Maense	Pleasance Forei Introduction Bruine Eastly Provine or d'Innead Bloeting Accenta Blood Trateflation Sickle Cell Disease Activitie VIS OR NO FOR THE FOLLO	Addina Hisp Faver Ensphysican Tuberculosis (TB) Diabetics Ucors Kishey Traditi Liven Disease Jaundice (Other than last WING OUESTIONS (B)	Hepatitis Thyraid Disease Gloscom Epilipty of Seitares Parting or Dizay Syells AIDS or AIDS Ratinod G HIV Positis Cold Sories N) Genital Herps	Veneres (Syphia) Drug A Psychia Caose Radiato Cheor Ingian Urangi FS: Piegar Gire Da	I Disease n, Generrhes Affectos rric Treatmen on Thomany dwoays ( Prosthesis la real Weight saily)	e Less
4 ARE YOU PRESENT	CONTINUE LY, OR HAVE YOU BEEN UND	E COMMENTS ON BAC	K IF NECESSARY	R7	1000	1 200
3. ARE YOU PRESENTS SUPPLEMENTS)?	LY TAKING ANY MEDICINE OF	DRUGS (OVER-THE-C	OUNTER / PRESCRIPTION	/HERBAL	0	No
6 ARE YOU ALLERGIC	TO ANY MEDICINE OR MATE	RIALS (INCLUDING LA	TEX)?		(1)	No
7. HAVE YOU EVER HA	D A REACTION TO LOCAL AN	ESTHETIC?			Yes	(Na)
E HAVE YOU EVER EX	PERIENCED ANY COMPLICAT	TON OR ILLNESS FOLL	OWING DENTAL TREATM	IENT?	Yes	6
9. DO YOU HAVE ANY	DISEASES OR CONDITIONS NO	OT MENTIONED ABOV	2		Yes	(NO)
10. HAVE YOU EVER B	EEN TOLD YOU WERE NOT EL	GIBLE TO BE A BLOO	D DONOR*		Yes	Ka
II. HAVE YOU EVER B	EEN TOLD TO TAKE ANTIBIOT	TICS PRIOR TO DENTAL	CARE?		Yes	C
12. DO YOU USE TORA SMOKE: CIGARETTES	CCO? (If Yes, Please Circle CIGAR PIPE S	e Type And Give Frequent MOKELESS: CHEWIN	(7) FREQUENCY: 5 TOBACCO SNUTT or DE		Yes	6
D. WOMEN - ARE YOU	PREGNANT? (If Yo	es, Please Circle Trimester 1 2 3			Yes	NO
Check Box If Cammer Back Of Fo	IN Added To SIGNATURE OF BA	THENDORE Local Consultan	a or Destance in a Minner)	84T 7/	26/2	00
+5 NTA' to E de No chule 1997 + TE for NTA' -5 TENJUM, HOOD PRESERVE DATE HOUD STIGNATURE DENTIST SIGNATURE	13 - D. persitic Availide (200 mg 1/25-3) Availide (200 mg 1/25-3) Availide (200 mg 1/25-3) Availide (200 mg 1/25-3) DATE R	+C (advision Coffin - an Wrophine - ), Tyloud / Ebiparch INCOMO PRESSURE DATE EVIEWER/DATE RE TO M advised at	A Anno Antonia A (Anno), ALA SING INCOMPARTMENTE VIEWERDATE REVIE	I - Linia Joseph L L Marte (John MARTS ON BA TE BLOOD PESSI WERDATE R	SA/ Ab	Hydrity All - A ATE DATE

# **PHOTOGRAPHS:**

# **Pre-treatment Clinical Photographs:**



Full Face Frontal View



Anterior View in MIP



Max Occlusal View



Man Occlusal View



Right Buccal View in MIP



Left Buccal View in MIP



Max Right Lingual View



Max Left Lingual View





Man Left Lingual View





Man Right Lingual View



Full Face Frontal View



Anterior View in CO



Max Occlusal View



Man Occlusal View





Right Buccal View in CO

Left Buccal View in CO



Max Right Lingual View



Max Left Lingual View



Man Right Lingual View



Man Left Lingual View

**Pretreatment:** 



Anterior View in MIP



Max Occlusal View



Man Occlusal View



Right Buccal View in MIP



Left Buccal View in MIP

### **Post-treatment:**



Anterior View in MIP





Max Occlusal View

Man Occlusal View



Right Buccal View in MIP



Left Buccal View in MIP

# **RADIOGRAPHS**:

# **Pretreatment:**





coup, including	, dia dia		NOU DEV	Det norm
Skeletal AP				
SNA (°)	74.3	81.4	4.4	-1.6 *
SNB (°)	76.6	78.2	3.9	-0.4
ANB (°)	-2.3	3.2	2.3	-2.4 **
A to N Vert (True Vert) (mm)	1.0	0.0	3.7	0.3
B to N Vert (True Vert) (mm)	5.8	-5.3	6.7	1.7 *
Pg to N Vert (True Vert) (mm)	8.1	-4.3	8.5	1.5 *
A-N Pernendicular (mm)	-5.2	1.1	2.7	-2.3 **
B-W Derpendicular (mm)	-6.2	-5.3	6.7	-0.1
Dog W Dermendiguler (mm)	E 2	0.2	2.0	1.2 *
Fog-N Felpendicular (mm)	-3.3	100.0	3.0	-1.3 -
MX Unit Length (LO-ANS) (mm)	90.3	100.9	3.9	-2.7 **
Mand Unit length (Lo-Gn) (mm)	127.0	131.0	4.6	-0.9
Mx/Md Diff (Co-Gn - Co-ANS) (mm)	36.6	30.0	3.9	1.7 *
Dental AP				
U1 - SN (°)	109.3	105.2	6.4	0.6
III - WA (°)	35.0	23.8	6.1	1.8 *
UI = WA ()	12.0	C C	2.7	2.4 **
UI - NA (IIII)	12.0	3.3	2.1	2.4 ""
01 - FH (*)	119.0	108.1	1.5	1.5 *
IMPA (L1-MP) (°)	93.6	95.3	6.6	-0.3
Ll - NB (°)	26.0	26.4	7.3	-0.1
Ll - NB (nm)	7.5	6.1	2.9	0.5
Ll Protrusion (L1-APo) (mm)	8.1	2.8	2.9	1.8 *
L1 to A-Po (°)	29.6	25.2	4.9	0.9
Wits Appraisal (mm)	0.6	-1.2	1.9	0.9
Interincisal Angle (U1-L1) (°)	121.3	126.6	10.0	-0.5
Overiet (mm)	1.4	2.0	1.0	-0.6
Pog - NB (mm)	1.7	2.4	2.5	-0.3
Heldement Dette (II) MD:Det MD) (%)	1.7	1.0	100.0	0.0
noidaway Racio (Li-MB:Pg-MB) (4)	4.0	1.0	100.0	0.0
PRIA (LI-PR) (*)	60.3	55.0	8.4	0.6
Skeletal Vert				
Total Anterior Face Ht (N-Me) (mm)	117.5	136.8	7.9	-2.4 **
Unner Face Height (N-105) (mm)	41.1	50.7	3.0	-4.8 ****
Lever Fore Height (NVS Me) (mm)	76 7	20 5	6.2	0.5
Novel Face neight (Ans-ne) (mm)	70.7	19.0	100.2	-0.5
Masar nerght (%)	35.0	43.0	100.0	-0.1
Post Facial Ht (Lo-Gh) (mm)	56.8	66.1	4.1	-2.3 **
Pfn:Afn (%)	48.3	60.0	100.0	-0.1
FMA (MP-FH) (°)	26.1	28.7	5.2	-0.5
SN - GoGn (°)	32.2	32.6	5.2	-0.1
Occ Plane to SN (°)	10.3	31.3	3.1	-6.8 *****
Occ Plane to FH (°)	0.6	11.5	2.6	-4.2 ****
FH - SN (°)	9.7	3.1	3.6	1.8 *
Dental Vert				
III - DD (IIIDH) (mm)	24 4	22.0	2.2	0.4
UI - FF (UADH) (MM)	34.4	33.U	3.2	0.4
L1 - HP (LADH) (mm)	46.6	48.9	3.0	-0.8
U6 - PP (UPDH) (mm)	28.7	20.5	3.2	2.6 **
L6 - MP (LPDH) (mm)	33.6	38.0	2.8	-1.6 *
Overbite (mm)	1.5	2.0	1.0	-0.5
Soft Tissue Profile				
Unner Lin to E-Plane (mm)	1.3	-4.0	2.0	2.6 **
Lower Lin to E-Plane (mm)	2 7	-2.0	2.0	2 4 **
STiggue N Vert (True Vert) to Upper Lin (an)	14 6	1 6	1.0	13 0 *****
, subsue a vero (nue vero) co opper bip (mm)	14.0	1.0	1.0	1910

# **Post-Treatment:**



#### **PERIODONTAL**:

#### **Pre-treatment:**





### PROBLEM LIST/DIAGNOSIS:

#### A. CHIEF COMPLAINT

- Pt presents with a primary chief complaint of "I have a gummy smile that I would like fixed."
- Pt also states that "I would like some of my back teeth replaced, what about those implants."
- Pt states hx of occasional, spontaneous discomfort #12
- Pt states hx of food impaction with discomfort between #28-29

# **B. MEDICAL/SYSTEMIC**

- ASA II
- BP 127/72 (7 Sept 10), 125/65 (23 Aug 10), 148/92 (26 Jul 10), 128/77 (8 Jun 10); Pulse 68; Resp.Rate 12; SpO2 99%; Temp. 98.8°
- Hx TIA 1999 due to thrombosis
- Dx HTN controlled with medication
- Dx GERD controlled with medication
- PSHx Hysterectomy 2005
- Medications: Avalide 300/12.5mg, Nexium prn, Tylenol or Ibuprofen prn dental pain, hx ASA 81mg sporadically - pt states is now taking regularly
- Drug Allergy: Codeine-N/V (per pt, probable sensitivity), Ceftin-N/V (per pt, probable sensitivity), Morphine-urticaria, Paxil-urticaria
- No tobacco use
- No alcohol consumption

### C. ORAL PATHOLOGY

- Noted a 4x4mm well-circumscribed radiopacity #2 edentulous area with apparent normal trabeculation
  - DiffDx: idiopathic osteosclerosis, condensing osteitis, retained root
- Noted a 3x8mm well-circumscribed radiopacity resembling a retained root #15 edentulous area
   DiffDx: Retained root, idiopathic osteosclerosis, condensing osteitis
- Noted a 1x2mm well-circumscribed radiopacity #1 mesial alveolar crest
  - DiffDx: Bony spicule/sequestrum, retained root
- Noted multiple, brown pigmented macules on the hard palate midline and posterior hard palate
   DiffDx: Racial pigmentation, oral melanotic macule
- Noted a well-defined mixed radiopaque/radiolucent lesion #20 periapical area with apparent cortical rim
  - DiffDx: Focal osseous dysplasia, condensing osteitis, aberrant trabeculation

### **D. RESTORATIVE**

- Moderate caries risk
- Fair OH
- Apparent normal salivary flow and quality
- Gen., mild, max and man spacing/open contacts with max anterior diastemata
- Symptomatic open contact #28-29
- Incisal edge fracture #9
- #12 unsupported tooth structure and questionable restorability
- Dx: Carious dentition #1-O, #3-OL, #5-B, #12-MOL, #20-DO, #29-D

### **E. ENDODONTICS**

- No current RCT
- #12 positive to cold test (EndoIce®) with relative increase in sensitivity and lingering discomfort, slight percussion sensitivity, no palpation sensitivity; #12 caries near pulp
- Remaining dentition normal cold tests and no percussion sensitivity
- No periapical lesions
- Dx: #12 symptomatic irreversible pulpitis, symptomatic apical periodontitis

### F. PERIODONTICS

- Fair OH, pt states brushing 2x/day and occasional flossing
- Hx of sporadic prophylaxis and no hx of periodontal therapy
- Initial Modified O"Leary plaque index score = 63%
- Initial bleeding index/BOP = 14%
- Gen. mild plaque accumulation with mild interproximal calculus accumulation
- Pt appears motivated to improve OH especially after disclosing solution
- No probing depths >3mm
- No gingival recession
- Unable to definitively locate CEJ of dentition, noted to be subgingival
- Clinical attachment levels range from -1 to 3mm
- BOP #1, 7, 8, 9,10, 11, 12, 20, 21, 24, 25, 26, 27, 28
- Symptomatic open contact #28-29 with food impaction
- Seibert Class I #4 edentulous area and maxillary left posterior area
- Seibert Class III bilateral mandibular posterior area
- Excessive gingival display max anterior
- Potential unesthetic or non-ideal gingival contours bilateral max posterior with only max anterior esthetic crown lengthening
- Attached gingival height #6-11 ranges from 8-10mm
- Attached gingival height #3, 5, 12, and 13 ranges from 3.5-5mm
- Potential insufficient interdental papilla and presence of "black triangles" with esthetic crown lengthening maxillary anterior
- Potential biologic width/dentogingival complex compromise #12 mesial
- Dx: Gen. plaque-induced gingivitis
- Dx: Excessive gingival display maxillary anterior due to altered passive eruption

### G. OCCLUSION AND TMJ

- No TMJ issues, range of motion limitations, or significant deviations/deflections
- CR does not equal MIP with 1<sup>st</sup> point of contact #3-29
- 1mm anterior shift from CR 1<sup>st</sup> point of contact to MIP
- Apparent bilateral group function occlusion in lateral excursive movements
- Supraeruption #1, 3 with #1 nearly occluding on man alveolar ridge
- MIO=51mm
- Decreased interarch space right posterior
- Bilateral posterior mild occlusal attrition with wear facets

### H. ORAL SURGERY

- #1 no apical proximity to max sinus nor root anomalies
- #12 no apical proximity to max sinus, two roots
- Apparent adequate alveolar bone height max bilateral edentulous posterior area with no max sinus proximity

• adequate alveolar bone height man bilateral edentulous posterior area ; no IAN proximity

## I. ORTHODONTICS

- Angle Class I bilateral canine, no molar occlusion
- Anteriorly divergent profile with acute nasolabial angle
- Vertical facial third lengths approximately equivalent
- Gen., mild, max and man spacing
- Max arch excess space=7.9mm
- Man arch excess space=3.5mm
- #6-11 excess space =3.8mm
- Overjet=2.5-3mm, Overbite=50%
- Max midline to right 1mm from facial midline
- Man midline to left 2mm from max midline
- Supraeruption #1, 3
- Mesial angulation #3

#### J. PROSTHODONTICS

- CR does not equal MIP
- 1mm anterior shift from CR 1<sup>st</sup> point of contact to MIP
- Apparent bilateral group function occlusion in lateral excursive movements
- Decreased interarch space right posterior
- Inadequate posterior occlusion, no molar occlusion
- Inadequate interarch space bilaterally for 2<sup>nd</sup> molar occlusion
- No posterior molar abutments max left and man bilateral
- Seibert Class I #4 edentulous area and maxillary left posterior area
- Seibert Classs III bilateral mandibular posterior area
- Adequate vertical stops on premolars
- Good crown:root ratio of dentition
- Good abutments #3, 5, 11, 13, 20, 29 for potential fixed or removable prosthesis
- Supraeruption #3 into occlusal plane
- Mesial inclination #3 with loss of space #4 edentulous area
- Undermined tooth structure #12 and questionable restorability
- Decreased clinical crown height max anterior with esthetic concerns
- Restore/replace # 4, 12, 14, 19, and 30 with a prostheses and/or implants

### **K. ESTHETICS**

- Pt desires decreased gingival display max anterior upon smiling
- Gen mild, max and man spacing/open contacts with max anterior diastemata
- Slight reverse smile right posterior due to supraeruption #3
- Upper lip length = 25mm
- Excessive gingival display due to altered passive eruption
- Max anterior teeth dimensions:

	Height (mm)	Width (mm)	H:W Ratio
#6	8.1	7.9	1.03 : 1
<b>#7</b>	6.4	7.5	0.85:1
<b>#8</b>	8.3	8.9	0.93:1
<b>#9</b>	7.5	8.9	0.84 : 1
#10	7.2	7.5	0.96 : 1
#11	8.9	8.1	1.10:1

# TREATMENT OBJECTIVE OVERVIEW:

- The patient is ASA II with no significant contraindications to dental treatment
- Monitor the patient"s HTN control throughout dental treatment
- Treatment will be provided utilizing evidence-based dentistry principles to restore the patient to optimal oral health, function, comfort, and esthetics
- A diagnostic mounting and waxing in CR will be completed to evaluate and provide a guide for the dental treatment plan beginning with the end in mind
- The dental treatment plan will address the patient"s chief complaint of excessive maxillary gingival display with an esthetic crown lengthening procedure
- The dental treatment plan will also address the patient"s chief complaint of inadequate posterior occlusion with implant-supported crowns restored to first molar occlusion
- The patient will be restored in CR/CO with a mutually protected articulation occlusal scheme
- Discuss OHI and nutritional/dietary counseling to ensure patient understands etiology of disease and prevention of disease reoccurrence
- Eval the OH status via the Modified O"Leary plaque index
- Oral prophylaxis and operative treatment to eliminate sources of infection and caries
- Evaluate and determine restorability #12; Assuming #12 non-restorable plan to extract with ridge preservation
- The patient will then be re-evaluated to assess the progression of the treatment plan according to the patient's chief complaint, desire to continue with proposed treatment plan, and response to preparatory/diagnostic/disease control phase
- Obtain CBCT with radiographic guides to evaluate potential implant sites #4, 12, 14, 19, 30 and need for bone grafts
- Limited orthodontic treatment including temporary anchorage devices (TADs) to intrude and rotate/translate #3 distally making adequate restorative space for implant-supported crowns #4, 30
- Esthetic crown lengthening of the maxillary arch due to altered passive eruption
- Placement of endosseous implants #4, 12, 14, 19, 30
- Equilibration to CR following occlusal device therapy
- Direct composite restorations #9 ILF for enamel fracture, #10-11 for diastema closure, and #29 M for closure of open contact to prevent food impaction
- Delivery of implant-supported POM crowns with custom abutments #4, 12, 14, 19, 30
- Fabricate occlusal device in CR
- Oral prophylaxis, implant, pathology, and occlusal device recalls/maintenance

# TREATMENT PLAN WITH RATIONALE:

#### A. EMERGENT PHASE

Treatment	Rationale
-No treatment indicated	-N/A

#### **B. SYSTEMIC/MEDICAL PHASE**

Treatment	Rationale
-Monitor the patient"s BP; avoid long-term NSAID	-Dx HTN controlled with medication, monitor HTN
therapy	control and refer to physician as needed
	-Long-term NSAID therapy potential antagonist to HTN
	control and ASA therapy
-Limit dose/eval response to opiods	-Hx N/V to codeine, sensitivity to opiods
-Avoid 2 <sup>nd</sup> generation cephalosporin antibiotics, limit	-Hx N/V to Ceftin, sensitivity to 2 <sup>nd</sup> generation
dose/eval response to penicillin-type and 1 <sup>st</sup> generation	cephalosporins; 1-7% crossreactivity between penicillin-
cephalosporins	type antibiotics and cephalosporins
-Avoid morphine-containing opiods; limit dose/eval	-Hx urticaria to morphine
response to opiods	
-Avoid Paxil; limit dose/eval response to SSRIs	-Hx urticaria to Paxil
-Evaluate the multiple, brown pigmented macules on the	-DiffDx of pathology noted is not significant and no tx is
hard palate midline/posterior hard palate for changes, the	indicated other than regular follow-up and eval for
radiopacities in #2, 15 edentulous areas for changes, and	changes
the mixed radiopaque/radiolucent lesion #20 apical area	
for changes on a regular basis throughout the treatment	

#### C. PREPARATORY/DIAGNOSTIC/DISEASE CONTROL PHASE

Treatment	Rationale
-Comprehensive oral eval; periodontal charting	-Documentation of existing restorations, defective restorations, caries, periodontal status of dentition, oral cancer screening, and additional findings to develop problem list
-Max/man diagnostic alginate impressions; duplicate x 3; pour master casts in Type V dental stone and duplicates in Type IV dental stone	<ul> <li>-Alginate: aqueous hydrocolloid; inexpensive, readily available, ease of use, good accuracy, sets quickly, hydrophilic, compatible with gypsum</li> <li>-Type V dental stone: excellent compressive strength</li> <li>-Type IV dental stone: less expansion (0.09%) than Type V, good compressive strength</li> <li>-Diagnostic casts used for diagnosis and tx planning, diagnostic waxing, radiographic guides/surgical stents, record bases</li> </ul>

-CR record and protrusive record	<ul> <li>-CR record made using leaf gauge and tongue to posterior palatal position technique: easy to adjust leaf gauge; objective evaluation of OVD; physiologic, repeatable, consistent, comfortable; deprogram neuromuscular apparatus</li> <li>-Protrusive record can be used to program condylar guidance/inclination on a Celenza Class 3b, Arcon, semi-adjustable articulator; safer record resulting in less steep/more shallow condylar inclination</li> <li>-Regisil PB used to make CR record and protrusive record due to accuracy, quick set, strength, not restrictive to mandibular movement, and ability to be trimmed/adjusted</li> </ul>
-Facebow transfer	-Records and transfers the position of the maxillary arch relative to the cranial base and horizontal axis of rotation to an articulator
-Intraoral and extraoral clinical photos	-Documentation of pre-treatment oral status and to develop problem list: adjunct to develop tx plan
-Full-mouth series digital radiographs; panoramic digital radiograph; lateral cephalometric radiograph	-Documentation of hard tissue status, existing restorations, defective restorations, caries, periodontal status of dentition, endodontic status of dentition, pathology -Lateral cephalometric radiograph to eval skeletal and dental relationships prior to orthodontic tx
-Diagnostic mounting in CR on Celenza Class 3b, Arcon, semi-adjustable articulator (Whip-Mix); program articulator with the protrusive record	<ul> <li>-Diagnostic mounting used for simulation of jaw movements, analysis of occlusal plane, analysis of occlusion/disclusion, visualization of anatomy and restorations, analysis of abutment length/angulation, diagnostic preparations, analysis of restorative space, morphology of tissue and edentulous ridges, and analysis of edentulous spans</li> <li>-Simulates physiologic mandibluar movement substituting mechanical equivalents for anatomic parts</li> <li>-Accepts facebow transfer and 80% of records where 75% of population is within 6mm of true horizontal hinge axis of rotation; protrusive record used to set condylar guidance/inclination using an average of 7 for Bennett angle/laterotrusion</li> <li>-Displays none-minimal arc of closure error in CR (condylar inclination and max occlusal plane angle remains the same with change in OVD)</li> <li>-Used for fixed and removable prostheses fabrication</li> </ul>
-3-piece cast analysis	-Allows for analysis of instant equilibration, eval of anterior-posterior coupling, eval of mutually-protected articulation, and reasonableness of restoring in CR -Diagnostic equilibration to CR
-Diagnostic waxing in CR	<ul> <li>Evaluate occlusal plane and occlusion/disclusion of proposed tx plan</li> <li>Evaluate anatomic contours of proposed tx plan</li> <li>CR with a mutually-protected occlusal scheme eliminates eccentric interferences, decreases trauma from occlusion (attrition/cusp fractures), develops class 3 lever where anterior disclusion is anterior to muscles generating less force, stabilizes occlusion, interrupts potentially destructive forces to TMJ, and is a repeatable position</li> </ul>

-Present and review the treatment plan with patient	- Gains patient acceptance and understanding according to
Oral manhylavia with anna ain aivel cooling, fluorida	Ensure notiont understands stieless of disease process
-Oral prophylaxis with supragnigival scaling, huonde	-Ensure patient understands etiology of disease process
treatment with 5% Nar varinsi, continue to eval the OH	Demonstel of riscus (colorities to reduce and bosterial load
status via the Modified O Leary plaque index and assess	-Removal of plaque/calculus to reduce oral bacterial load
bleeding index; discuss OHI and nutritional/dietary	and the reservoir/niche for oral bacteria and/or toxins
counseling; KX: Prevident 5000 Plus dentifice, brush	-Modified O Leary plaque index to ensure patient displays
teeth bid with pea-sized amount, expectorate	adequate plaque removal, goal $\geq 80\%$
	-Assess bleeding index, <10% considered gingival health
	-Ensure low and infrequent carbonydrate/refined sugar
	consumption
	-Fluoride treatment with Vanish 5% NaF varnish; ease of
	handling, slowly dissolved by saliva, high-dose fluoride
	(22,500ppm), inhibits bacterial metabolism, inhibits
	demineralization, enhances remineralization
	-Fluoride treatment with Prevident 5000 Plus dentifrice;
	ease of use, consistent fluoride exposure (5000ppm),
	inhibits bacterial metabolism, inhibits demineralization,
	enhances remineralization
-Operative tx #3 OL amalgam	-#3 recurrent caries
	-Valiant Ph.D amalgam: admixture of lathe-cut and single
	composition spherical; high copper amalgam nearly
	eliminating Gamma 2 phase; contains palladium for early
	strength and reinforce gamma 1 phase; fine particle size
	for a dense set; ease of use and condensability
-Operative tx #5 B composite	-#5 carious lesion
	-Optibond FL DBA: 4 <sup>th</sup> generation, 3 step Etch and Rinse;
	97% retention at 13 yrs, gold-standard for DBA; separate
	primer and adhesive; 48% filled with good bond strengths
	and less microleakage; radiopaque; use 37.5% phosphoric
	acid etch
	-Filtek Supreme Ultra composite: nanocomposite; 78%
	filled by weight; good strength, good wear resistance, and
	good esthetics/polishability; universal use for both
	anterior and posterior restorations; nanoclusters wear
	similar to adjacent resin matrix and are smaller than
	microfilled formed silica
	-Cure using a 3 <sup>rd</sup> generation LED dual-emission spectrum
	light; ease of use, efficient light, longevity; reportedly able
	to cure camphorquinone, PPD, and TPO photoinitiators
-Operative tx #20 DO amalgam, M pit composite	-#20 carious lesions
	-Amalgam, DBA, and composite as previously noted
-Operative tx #29 D composite	-#29 carious lesion
	-DBA and composite as previously noted

on
'n
(1-
tion
e width
e wiadii
ned
ofuse
roical
rgicai
nd
ft
lt Ipol
Ipai
nding
inesia
vhere
es
ast
iction,
d
lation
tion of
curred
ectrum
of oral
on of
ous

#### **D. RE-EVALUATION PHASE**

Treatment	Rationale
-Evaluate the OH status via the Modified O''Leary plaque	-Ensure patient is maintaining good OH to eliminate and
index; discuss OHI and dietary counseling	prevent the disease process
-Evaluate the corrective/restorative treatment plan	-Evaluate the patient response to the
following the preparatory/diagnostic/disease control phase	preparatory/diagnostic/disease control phase and ensure is
	conducive to the corrective/restorative treatment plan
	-Ensure the patient desires to continue with the proposed
	treatment plan

# E. CORRECTIVE/RESTORATIVE PHASE

Treatment	Rationale
-Mountings completed in CR on Celenza Class 3b, Arcon, semi-adjustable articulator (Whip-Mix)	-As previously noted
-Obtain CBCT for potential implant sites #4, 12, 14, 19, 30 with radiographic guide in place -Evaluate 3-dimensional osseous structure relative to proposed implant site angulation and restoration; evaluate adequate bone present and need for bone graft	-Radiographic guide fabricated based on dx waxing -CBCT in iCAT with following settings: 16cm x 6cm, 0.2 voxel, 14.7sec – higher resolution, smaller FOV, less radiation exposure
-Limited orthodontic tx /TAD placement #3	-Place band on #3 and B/L buttons on #1 -Mondeal Lomas Quattro 1.5x7mm TADs to provide sufficient anchorage to move #3 distally and intrude -Utilize #1 as additional anchorage to move #3 distally
-Orthodontic follow-up appointments q 2-4 weeks for 6 months; max essix-type retainer	<ul> <li>-Change closed powerchains q2-4 weeks to maintain consistent, low force/pressure</li> <li>-Monitor movement #3</li> <li>-Fabricate 2mm thick essix-type retainer to maintain position #3 until implant-supported crowns delivered</li> </ul>
-Stage I endosseous implant placement #19 with bone graft/membrane	<ul> <li>Biomet3i, Full Osseotite Certain 4x11.5mm implant: titanium alloy, acid-etched surface promotes osseointegration to implant platform, internal hex, internal anti-rotation</li> <li>Autogenous bone graft: osteogenic, osteoinductive, osteoconductive; placed adjacent to implant</li> <li>Bio-Oss bone graft: bovine bone graft; osteoconductive; placed adjacent to autogenous bone graft; ease of use, maintains space well, does not require 2<sup>nd</sup> surgical site</li> <li>OsseoGuard membrane: resorbable bovine collagen membrane, resorption in approximately 26-38 weeks</li> <li>Bone graft/membrane necessary for minimal 1-2mm thickness buccal bone adjacent to implant</li> <li>Use surgical stent converted from radiographic guide to place implant at correct angulation and position determined from dx waxing</li> <li>Place implant platform approximately 3-4mm apical to adjacent teeth buccal CEJ to allow for normal emergence profile and esthetics</li> </ul>
-Stage I endosseous implant placement #30	<ul> <li>Biomet3i, Full Osseotite Certain 4x11.5mm implant: titanium alloy, acid-etched surface promotes osseointegration to implant platform, internal hex, internal anti-rotation</li> <li>Use surgical stent converted from radiographic guide to place implant at correct angulation and position determined from dx waxing</li> <li>Place implant platform approximately 3-4mm apical to adjacent teeth buccal CEJ to allow for normal emergence profile and esthetics</li> </ul>

-#5-11 esthetic crown lengthening	<ul> <li>-Excessive gingival display due to altered passive eruption</li> <li>-Position the gingival margin #5-11 in a more apical position at the CEJ</li> <li>-Osteoplasty and ostectomy to achieve 3mm between CEJ and coronal position of alveolar bone</li> <li>-#5-11 buccal/facial flap reflection only preserving lingual papilla to decrease risk of post-op recession and formation of black triangles</li> </ul>
-1, 2, 4, 8 week POT for #5-11 estiletic crown lengthening	-Evaluate for normal heating and plaque removal
-Stage I endosseous implant placement #4; crown lengthening #3; extraction #1	<ul> <li>Biomet3i, Full Osseotite Certain 4x11.5mm implant: titanium alloy, acid-etched surface promotes osseointegration to implant platform, internal hex, internal anti-rotation</li> <li>Use surgical stent converted from radiographic guide to place implant at correct angulation and position determined from dx waxing</li> <li>Place implant platform approximately 3-4mm apical to adjacent teeth buccal CEJ to allow for normal emergence profile and esthetics</li> </ul>
-Stage I endosseous implant placement #12 and 14; crown lengthening #13	<ul> <li>-#12 Biomet3i, Full Osseotite Certain 4x11.5mm and #14 Biomet3i, Full Osseotite Certain 5x11.5mm implants: titanium alloy, acid-etched surface promotes osseointegration to implant platform, internal hex, internal anti-rotation</li> <li>-Use surgical stent converted from radiographic guide to place implant at correct angulation and position determined from dx waxing</li> <li>-Place implant platform approximately 3-4mm apical to adjacent teeth buccal CEJ to allow for normal emergence profile and esthetics</li> </ul>
-1, 2, 4, 8 week POT for stage I implant placements	-Evaluate for normal healing and plaque removal
-Max/man alginate impressions; occlusal device record; fabricate occlusal device in CR	<ul> <li>-Fabricate max occlusal device using Ortho-Jet PMMA acrylic in CR and adjust to achieve mutally-protected articulation</li> <li>-Occlusal device record made in CR position open 2-3mm for adequate thickness of acrylic</li> <li>-Regisil PB used to make occlusal device record as previously noted</li> </ul>
-Occlusal device therapy for CR equilibration	-Use of occlusal device therapy in CR to evaluate patient response to new mandibular position; evaluate patient comfort and function in CR position prior to irreversible CR equilibration -Allows for reversible treatment to a CR position with mutually-protected articulation
-CR equilibration following occlusal device therapy	-CR with a mutually-protected occlusal scheme eliminates eccentric interferences, decreases trauma from occlusion (attrition/cusp fractures), develops class 3 lever where anterior disclusion is anterior to muscles generating less force, stabilizes occlusion, interrupts potentially destructive forces to TMJ, and is a repeatable position -Complete CR equilibration of dentition following occlusal device therapy

-Operative tx #9 ILF	-#9 ILF enamel fracture
*	-DBA and composite as previously noted
-Operative tx #10 DLF, 11 MLF	-#10-11 diastema, previously unrestored dentition,
^ _	minimally invasive treatment ideal
	-DBA and composite as previously noted
-Operative tx #29 M interproximal	#28-29 open contact with symptomatic food impaction,
	previously minimally restored dentition, minimally
	invasive treatment ideal
	-DBA and composite as previously noted
-Stage II implant surgery for healing abutment placement	-#4, 12, 19, 30 Biomet3i Encode 4.1/5/4mm and #14
#4, 12, 14, 19, 30	Biomet3i Encode 5/6/4mm healing abutments
	-Verified healing abutment seating via radiographs
	-Placement of healing abutments with slightly wider
	emergence profile
	-Position gingival margins with minimal 2mm band/collar
	of keratinized gingival tissue around healing abutment
-1. 2. 4 week POT for stage II implant surgery	-Evaluate for normal healing and plaque removal
-Implant level impression #4_12_14_19_30	-Extrude VPS impression material: addition silicone: no
	by-product and therefore very dimensionally stable good
	accuracy, improved wettability, thixotropic properties.
	compatible with gypsum
	-Open tray impression technique: allows impression
	coping to remain in impression material, less potential for
	error
	-Verified impression coping seating via radiographs
	-Allows for accurate reproduction of implant position
	relative to adjacent dentition
-Custom abutment try-in #4, 12, 14, 19, 30; CR record	-Jelenko Firmilay II type III gold custom abutments (73%
	Au)
	-Verified custom abutment seating via radiographs
	-Gold custom abutments allow for customization of
	emergence profile and margin location
	-Gold custom abutments result in a more pleasant, warm
	tone to underlying gingival tissue
	-Regisil PB used to make CR record as previously noted
-Delivery of custom abutments and implant-supported	-Biomet 3i Certain Gold-Tite hexed screw torqued to
POM crowns #4, 12, 14, 19, 30	20N-cm
	-Verified impression coping seating via radiographs
	-Abutment access sealed with 0.12% CHX-soaked pellet
	and composite as previously noted
	-Cement using RelyX Luting Plus: RMGI cement; good
	tensile and compressive strength, ease of use, low
	microleakage, low solubility, low film thickness
	-POM crown fabricated from Olympia high noble metal
	(51.5% Au, 38.5% Pd) and IPS InLine PoM ceramic;
	POM ceramic uses lost-wax technique with improved
	ability to control occlusion and contours

-Max/man alginate impressions; occlusal device in CR; fabricate occlusal device in CR	<ul> <li>-Alginate impressions as previously noted</li> <li>-Fabricate max occlusal device using Eclipse resin-type material: less volumetric shrinkage than PMMA acrylics (3% vs 7%), ease of use, handles like wax, improved ability to control occlusion</li> <li>-Regisil PB used to make occlusal device record as previously noted</li> </ul>
-Delivery max occlusal device in CR	-Occlusal device in CR as previously noted

### F. MAINTENANCE PHASE

Treatment	Rationale
-Oral prophylaxis q 6 months; fluoride treatment with 5% NaF varnish; continue to eval the OH status via the Modified O'Leary plaque index and assess bleeding index; discuss OHI and nutritional/dietary counseling	-As previously noted
-Implant maintenance/recall and oral pathology recall q 12	-Evaluate gingival health/response and osseous
months	structure/bone levels of implant; evaluate crown and
	abutment integrity
	-Evaluate/monitor changes of previously noted oral
	pathology lesions
-Occlusal device recall q 6 months	-Evaluate fit and occlusion/disclusion to ensure a
_	mutually-protected articulation occlusal scheme is
	maintained

# **Charting Of Treatment Rendered:**



#### Prognosis:

- Periodontal prognosis is good
- Restorative prognosis is good
- Esthetic prognosis is good with the ability to apically position the maxillary gingival margin via esthetic crown lengthening, closing the diastemata with direct composite restorations, and replacing the missing maxillary teeth with implant-supported crowns
- Prosthetic/occlusal prognosis is good with the ability to attain first molar occlusion with implantsupported crowns in CR with mutually-protected articulation and use of an occlusal device

#### **Medical/Specialty Consults:**

■ N/A

#### **PROSTHODONTIC LAB WORK AUTHORIZATIONS:**

12. Type of Prosthesis or Restoration Dx impressions and duplication	13. Shade and Mold by Guide	14. Date Delivere
5. Prosthesis Design	(32) MAN	DIBULAR
Request(s) (Check appropriate box(es)) 18. Process 19. Fully Fabricat	16. Framework Only 17 te 20. Bisque Bake	21. Consultation
		-
<ol> <li>22. Clinician's Remarks/Instructions</li> <li>Please pour max/man dx impripin for mounting.</li> <li>Please duplicate max/man cast and pin for mounting.</li> </ol>	essions in die keen stohe, two ts and pour in die keen stone,	<ul> <li>Other (See romar</li> <li>step pour, and</li> <li>two-step pour,</li> </ul>
<ol> <li>22. Clinician's Remarks/Instructions</li> <li>Please pour max/man dx impripin for mounting.</li> <li>Please duplicate max/man cast and pin for mounting.</li> <li>Thank you.</li> </ol>	tion Record 24. Radiographs 25.	Other (See roman -step pour, and two-step pour,
<ol> <li>22. Clinician's Remarks/Instructions</li> <li>Please pour max/man dx impripin for mounting.</li> <li>Please duplicate max/man cast and pin for mounting.</li> <li>Thank you.</li> </ol>	tion Record 24. Radiographs 25.	Other (See roman -step pour, and two-step pour,
<ol> <li>22. Clinician's Remarks/Instructions</li> <li>Please pour max/man dx impripin for mounting.</li> <li>Please duplicate max/man cast and pin for mounting.</li> <li>Thank you.</li> </ol>	ion Record 24. Radiographs 25.	Other (See roma -step pour, and two-step pour,

Max/Man Dx Casts



#### <u>#4, 12, 14, 19, 30 Custom Abutments</u>



# Max Eclipse Occlusal Device

12. Type of Prosthesis or Restoration Max occlusal device - Ecclipse	13. Shade and Mold by Guide	14. Date Deliver
15. Prosthesis Design	~	
ano	(1) (32)	6
à c	D Dig MANE	DIBULAR (19)
Ø 9	R (m)	Find
(D)	2 3	(20)
23 MAXILLARY	& Ph	and
60	(10)	N3
Request(s) (Check appropriate powlet))	16 Framework Doly 12	TT Set up
and monthly forward of the strength of the str		
18. Process 19. Fully Fabricate	20. Bisque Bake	21. Consultation
22 Diagnostic Casts 23 Jaw Rolate	on Record 24. Radiographs 25.	Other (See rema
26. Clinician's Remarks/Instructions		
Please fabricate a max Eclipse occ	lusal device as follows:	
1. Zero degree block-out on max	cast	
2. Follow design on master cast to	shape Eclipse to achieve full	arch contacts it
CO/mutually-protected articulation	n with anterior disocclusion, j	just enough ram
to allow clearing of man posterior	teeth in lateral moves.	
<ol><li>Complete occlusal contacts prio</li></ol>	or to removal from cast. Finis	sh/polish.
Thank you.		
27. Typed Name and Grade of Dental Officer	he signing	
Maj N DuVall	20. Signature	
DD Form 2322, OCT 83	Dental Laborati	ory Work Authorizat
DD Form 2322, OCT 83	Dental Laborate	ory Work Authorizat
DD Form 2322, OCT 83	Paul Re	ory Work Authorizat